MINNEAPOLIS & SAN ANTONIO--(BUSINESS WIRE)--Nov. 17, 2009--
Medtronic, Inc. (NYSE:MDT) today announced the grand opening of its new
Diabetes Therapy Management and Education Center in San Antonio. The new
operation provides customer care and education for patients and
healthcare professionals using Medtronic insulin pumps, continuous
glucose monitoring and therapy management software for the treatment of
diabetes.
Company officials and San Antonio community representatives cut the
ribbon at the Center, which currently employs more than 200 diabetes
therapy professionals dedicated to supporting Medtronic customers. The
company anticipates hiring nearly 1,400 people within the next five
years.
“Not only is this facility a Center of Excellence for diabetes therapy
management, it supports Medtronic’s commitment to accelerating the pace
of innovation to improve patients’ lives,” said Katie Szyman, president
of the Diabetes business and senior vice president at Medtronic. “We are
delighted to be able to expand our business operations in the San
Antonio community, as well as support South Texas by bringing new jobs
to the area.”
Medtronic’s Diabetes Therapy Management and Education Center is fully
integrated with the Diabetes business, which is based in Northridge,
Calif., and focused on providing customer experience excellence.
Medtronic continues to invest in both its Northridge and San Antonio
operations to provide world class customer care.
About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com)
is the world leader in advanced diabetes management solutions, including
integrated diabetes management systems, insulin pump therapy, continuous
glucose monitoring systems and therapy management software.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical
technology, alleviating pain, restoring health and extending life for
millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic’s Annual Report on Form 10-K for
the year ended April 24, 2009. Actual results may differ materially from
anticipated results.
Source: Medtronic, Inc.
Medtronic, Inc.
Public Relations
Steve Cragle, 763-505-2345
or
Investor
Relations
Jeff Warren, 763-505-2696
